Starboard Focused on Kenvue's Struggling Unit
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
Kenvue needs to fix its skin, health & beauty segments, Starboard's Jeff Smith says (update)
Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...
Starboard Scolds Pfizer Over $20 Billion Value Destruction (2)
Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...
Starboard calls for Pfizer board to ‘hold management accountable’
Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...
What activist hedge fund Starboard wants from Pfizer
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
Starboard Value CEO Jeff Smith: Pfizer needs to do a better job disciplining itself on investments
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
BioSpace21h
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Starboard Says Kenvue's Skin Health Segment Is Weighing on Performance
NEW YORK (Reuters) - Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty ...
Starboard Chief Criticizes Pfizer’s R&D Investments
Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...